Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 3, 2013, Pages 480-487

  Nanra, Jasdeep S ^a   Buitrago, Sandra M ^a   Crawford, Shomari ^a   Ng, Jennifer ^a   Fink, Pamela S ^a   Hawkins, Julio ^a   Scully, Ingrid L ^a   McNeil, Lisa K ^a   Aste Am Éaga, Josémiguel ^a   Cooper, David ^a   Jansen, Kathrin U ^a   Anderson, Annaliesa S ^a  

^a Pfizervaccine Research   (United States)

Author keywords

Anti capsular polysaccharide antibodies; MRSA; MSSA; Opsonophagocytic antibody assay; S. aureus; Staphylococcal protein A; Vaccine

Indexed keywords

ANTIBODY; BACTERIAL POLYSACCHARIDE; CAPSULAR POLYSACCHARIDE; CAPSULAR POLYSACCHARIDE ANTIBODY; PROTEIN A; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; COMPLEMENT; OPSONIN; STAPHYLOCOCCUS PROTEIN A; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIBODY TITER; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL SURFACE; CONFERENCE PAPER; CONTROLLED STUDY; IMMUNE EVASION; IMMUNOASSAY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; OPSONIZATION; OPSONOPHAGOCYTIC ANTIBODY ASSAY; PHAGOCYTOSIS; PROTEIN EXPRESSION; RHESUS MONKEY; STAPHYLOCOCCUS AUREUS; ANIMAL; BACTERIAL CAPSULE; IMMUNOLOGY; PATHOGENICITY;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; COMPLEMENT SYSTEM PROTEINS; IMMUNE EVASION; MACACA MULATTA; OPSONIN PROTEINS; PHAGOCYTOSIS; STAPHYLOCOCCAL PROTEIN A; STAPHYLOCOCCUS AUREUS; VIRULENCE FACTORS;

EID: 84874685977     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23223     Document Type: Conference Paper

References (33)

1. Gorwitz RJ, Kruszon-Moran D, McAllister SK, McQuillan G, McDougal LK, Fosheim GE, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008; 197:1226-34; PMID:18422434; http://dx.doi.org/10.1086/533494. (Pubitemid 351632753)
2. .Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, Albrecht V, Limbago B, et al. EMERGEncy ID NET Study Group. Prevalence of methicillin-resistant staphylococcus aureus as an etiology of communityacquired pneumonia. Clin Infect Dis 2012; 54:1126-33; PMID:22438343; http://dx.doi.org/10.1093/cid/cis022.
3. Nimmo GR. USA300 abroad: global spread of a virulent strain of community-associated methicillinresistant Staphylococcus aureus. Clin Microbiol Infect 2012; 18:725-34; PMID:22448902; http://dx.doi.org/10.1111/j.1469-0691. 2012.03822.x.
4. Tong SY, Chen LF, Fowler VG Jr. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance? Semin Immunopathol 2012; 34:185-200; PMID:22160374; http://dx.doi.org/10.1007/s00281-011-0300-x.
5. Thakker M, Park JS, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 1998; 66:5183-9; PMID:9784520. (Pubitemid 29044607)
6. Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, et al. Challenges for the evaluation of Staphylococcus aureus protein basedvaccines: monitoring antigenic diversity. Hum Vaccin 2011; 7(Suppl):51-9; PMID:21245656; http://dx.doi.org/10.4161/hv.7.0.14562.
7. Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, et al. Laboratory and clinical evaluation of conjugatevaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 1993; 61:1023-32; PMID:8432585. (Pubitemid 23059663)
8. Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP)vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64:1659-65; PMID:8613375.
9. Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997; 65:4146-51; PMID:9317020.
10. Peterson PK, Verhoef J, Sabath LD, Quie PG. Effect of protein A on staphylococcal opsonization. Infect Immun 1977; 15:760-4; PMID:870431. (Pubitemid 8077418)
11. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcalvaccines. Clinvaccine Immunol 2006; 13:165-9; PMID:16467321; http://dx.doi.org/10.1128/ CVI.13.2.165-169.2006. (Pubitemid 43383782)
12. Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications forvaccine design.vaccine 2009; 27:3276-80; PMID:19200819; http://dx.doi.org/10.1016/j.vaccine.2009.01. 062.
13. Dassy B, Stringfellow WT, Lieb M, Fournier JM. Production of type 5 capsular polysaccharide by Staphylococcus aureus grown in a semisynthetic medium. J Gen Microbiol 1991; 137:1155-62; PMID:1865184; http://dx.doi.org/10. 1099/00221287-137-5-1155.
14. Stephan F, Yang K, Tankovic J, Soussy CJ, Dhonneur G, Duvaldestin P, et al. Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 2002; 30:315-22; PMID:11889301; http://dx.doi.org/10.1097/00003246-200202000-00009. (Pubitemid 34158113)
15. Verbrugh HA, Peterson PK, Nguyen BY, Sisson SP, Kim Y. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. J Immunol 1982; 129:1681-7; PMID:7108223. (Pubitemid 12031113)
16. Verdrengh M, Tarkowski A. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun 1997; 65:2517-21; PMID:9199413. (Pubitemid 27264071)
17. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-40; PMID:5216294.
18. Dinauer MC. Disorders of neutrophil function: an overview. Methods Mol Biol 2007; 412:489-504; PMID:18453130; http://dx.doi.org/10.1007/978-1-59745- 467-4-30.
19. Heyworth PG, Cross AR, Curnutte JT. Chronic granulomatous disease. Curr Opin Immunol 2003; 15:578-84; PMID:14499268; http://dx.doi.org/10.1016/S0952- 7915(03)00109-2. (Pubitemid 37130200)
20. Johnston RB Jr., Keele BB Jr., Misra HP, Lehmeyer JE, Webb LS, Baehner RL, et al. The role of superoxide anion generation in phagocytic bactericidal activity. Studies with normal and chronic granulomatous disease leukocytes. J Clin Invest 1975; 55:1357-72; PMID:166094; http://dx.doi.org/10.1172/JCI108055. (Pubitemid 8036498)
21. Quie PG, White JG, Holmes B, Good RA. In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood. J Clin Invest 1967; 46:668-79; PMID:6021213; http://dx.doi.org/10.1172/JCI105568.
22. Cunnion KM, Benjamin DK Jr., Hester CG, Frank MM. Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4, and C5 in survival by mice of Staphylococcus aureus bacteremia. J Lab Clin Med 2004; 143:358-65; PMID:15192652; http://dx.doi.org/10.1016/j.lab.2004.03.005. (Pubitemid 38859674)
23. Cunnion KM, Lee JC, Frank MM. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun 2001; 69:6796-803; PMID:11598052; http://dx.doi.org/10.1128/IAI.69.11.6796-6803.2001.
24. Cunnion KM, Zhang HM, Frank MM. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect Immun 2003; 71:656-62; PMID:12540542; http://dx.doi.org/10.1128/IAI.71.2.656-662.2003. (Pubitemid 36150756)
25. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359-95; PMID:1889047.
26. Mickenberg ID, Root RK, Wolff SM. Leukocytic function in hypogammaglobulinemia. J Clin Invest 1970; 49:1528-38; PMID:4194088; http://dx.doi.org/10.1172/JCI106370.
27. Xu S, Arbeit RD, Lee JC. Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1992; 60:1358-62; PMID:1548061.
28. Mishra RP, Mariotti P, Fiaschi L, Nosari S, Maccari S, Liberatori S, et al. Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. J Infect Dis 2012; 206:1041-9; PMID:22829645; http://dx.doi.org/10.1093/infdis/jis463.
29. Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, et al. Development of a multicomponent Staphylococcus aureusvaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother 2012; 8:8; PMID:22922765.
30. Daum RS, Spellberg B. Progress toward a Staphylococcus aureusvaccine. Clin Infect Dis 2012; 54:560-7; PMID:22186773; http://dx.doi.org/10.1093/cid/ cir828.
31. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 2012; 15:92-9; PMID:22088393; http://dx.doi.org/10.1016/j.mib.2011.10.012.
32. Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB. Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharidevaccine efficacy. Clin Infect Dis 2012; 55:1188-97; PMID:22806596; http://dx.doi.org/10.1093/cid/cis624.
33. Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, et al. A recombinant clumping factor A-containingvaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clinvaccine Immunol 2012; 19:1641-50; PMID:22896688; http://dx.doi.org/10.1128/ CVI.00354-12.